Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership
Evotec (NASDAQ:EVO) announced receipt of a US$5 million milestone payment after the U.S. FDA accepted an Investigational New Drug (IND) application for a collaboration-developed CELMoD™ drug candidate.
The candidate, from Evotec's strategic protein degradation partnership with Bristol Myers Squibb initiated in 2018 and expanded in 2022, is expected to enter Phase 1 in 2026. The announcement highlights Evotec's multi-omics and AI-supported drug discovery role and frames the IND acceptance as a regulatory milestone validating the collaboration's progress toward first-in-class molecular glue degraders.
Evotec (NASDAQ:EVO) ha annunciato di aver ricevuto un pagamento milestone di US$5 milioni dopo che la FDA statunitense ha accettato una domanda Investigational New Drug (IND) per un candidato CELMoD™ sviluppato in collaborazione.
Il candidato, frutto della partnership strategica di Evotec per la degradazione proteica con Bristol Myers Squibb avviata nel 2018 e ampliata nel 2022, è previsto entrare in Fase 1 nel 2026. L'annuncio mette in risalto il ruolo di Evotec nella scoperta di farmaci supportata da multi-omics e AI e presenta l'accettazione dell'IND come una tappa regolatoria che convalida i progressi della collaborazione verso degradanti molecolari di tipo glue di prima classe.
Evotec (NASDAQ:EVO) anunció la recepción de un pago por hito de US$5 millones después de que la FDA de EE. UU. aceptara una solicitud Investigational New Drug (IND) para un candidato a fármaco CELMoD™ desarrollado en colaboración.
El candidato, fruto de la asociación estratégica de Evotec para la degradación de proteínas con Bristol Myers Squibb iniciada en 2018 y ampliada en 2022, se espera que entre en Fase 1 en 2026. El anuncio destaca el papel de Evotec en el descubrimiento de fármacos apoyado por multi-omicas e IA y enmarca la aceptación del IND como un hito regulatorio que valida el progreso de la colaboración hacia degradadores moleculares de pegamento de primera clase.
에보텍(Evotec, NASDAQ:EVO)은 미국 FDA가 협력 개발 CELMoD™ 약물 후보물질에 대한 임상시험신약신청(IND)를 접수한 뒤 미화 5백만 달러의 마일스톤 지불금을 수령했다고 발표했습니다.
이 후보물질은 2018년 시작되어 2022년에 확대된 Evotec와 Bristol Myers Squibb의 전략적 단백질 분해 파트너십의 산물로, 2026년 1상 진입 예정입니다. 발표는 다중 오믹스(multi-omics) 및 AI 기반 약물 발굴 역량을 강조하고 IND 접수를 협력의 1등급 분자 글루(degraders) 후보로 규제적 이정표로 제시합니다.
Evotec (NASDAQ:EVO) a annoncé avoir reçu un paiement d'étape de 5 millions de dollars américains après que la FDA américaine a accepté une demande Investigational New Drug (IND) pour un candidat médicamenteux CELMoD™ développé en collaboration.
Le candidat, issu du partenariat stratégique d'Evotec pour la dégradation des protéines avec Bristol Myers Squibb lancé en 2018 et élargi en 2022, devrait entrer en phase 1 en 2026. L'annonce met en évidence le rôle d'Evotec dans la découverte de médicaments guidée par multi-omiques et IA et présente l'acceptation de l'IND comme une étape réglementaire validant les progrès de la collaboration vers des degraders moléculaires Glue de première classe.
Evotec (NASDAQ:EVO) gab bekannt, dass es eine Meilensteinzahlung von US$5 Millionen erhalten hat, nachdem die US-FDA einen Antrag auf Investigational New Drug (IND) für einen in der Zusammenarbeit entwickelten CELMoD™-Kandidaten akzeptiert hat.
Der Kandidat, aus Evotecs strategischer Partnerschaft zur Proteindegradation mit Bristol Myers Squibb, gestartet 2018 und erweitert 2022, wird voraussichtlich in Phase 1 im Jahr 2026 eintreten. Die Ankündigung hebt Evotecs Rolle bei der Entdeckung von Arzneimitteln durch Multi-Omics und KI-Unterstützung hervor und stellt die IND-Akzeptanz als regulatorischen Meilenstein dar, der den Fortschritt der Zusammenarbeit hin zu first-in-class Molekular-Glue-Degraders bestätigt.
إيفوتيك (NASDAQ:EVO) أعلنت استلام دفعة مرحلية بقيمة 5 ملايين دولار أمريكي بعد أن قبلت هيئة الغذاء والدواء الأمريكية طلباً دواء جديد تجريبي (IND) لكائن دوائي CELMoD™ طورته بالتعاون.
هذا المرشح، الناتج عن شراكة Evotec الاستراتيجية في تحلل البروتين مع Bristol Myers Squibb التي بدأت في 2018 وتوسعت في 2022، من المتوقع أن يدخل المرحلة الأولى في 2026. تسلط البيان الضوء على دور Evotec في اكتشاف الأدوية المدعوم بالـ multi-omics والذكاء الاصطناعي، ويعرض قبول IND كمعلم تنظيمي يؤكد تقدم التعاون نحو degraders جزيئية لاصقة من الدرجة الأولى.
- US$5.0M milestone payment received after IND acceptance
- FDA IND acceptance for CELMoD™ candidate triggers clinical pathway
- Phase 1 start expected 2026, advancing clinical timeline
- Established collaboration with Bristol Myers Squibb since 2018 (expanded 2022)
- Candidate remains pre-approval with clinical efficacy unproven until trials complete
- No financial guidance or revenue impact disclosed from the milestone
Insights
IND acceptance and a
Evotec received a
The business mechanism is straightforward: regulatory acceptance triggered a contractual payment, validating a preclinical-to-clinical milestone under the collaboration. This outcome converts partnership R&D work into near-term clinical de-risking and delivers a concrete cash inflow of
Key dependencies and risks remain confined to clinical development and regulatory progress; the IND acceptance is a necessary but not sufficient step toward commercialization. Watch the initiation and early safety/PK readouts from the Phase 1 study in
Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populations
FDA clearance of IND application triggered a US
$ 5 m milestone payment to Evotec
HAMBURG, DE / ACCESS Newswire / November 12, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced that it has received a US
Initiated in 2018, the collaboration combines Evotec's high-performance multi-omics screening as well as AI-supported data analytics and drug design capabilities with Bristol Myers Squibb's industry-leading library of CELMoDs™. The collaboration, expanded in 2022, continues to deliver on its goal to identify novel molecular glue degraders for high-value targets in the field of oncology and beyond.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are excited to have reached this important achievement in our collaboration with Bristol Myers Squibb, and to move one step closer to bringing the first compound of our molecular glue degrader pipeline to the clinic. This IND acceptance represents not only a major scientific and regulatory milestone but also validates the strength of our collaboration and emphasizes the enormous potential for delivering multiple first-in-class products to market."
About molecular glue degraders
Conventional small molecule therapeutics work via a drug-induced interference with a protein activity. This limitation to agonistic or antagonistic functions renders about
Molecular glue degraders are compounds that induce interactions between an E3 ubiquitin ligase and a molecular target. The induced interaction results in ubiquitination and subsequent degradation of the recruited protein. Through this mechanism of action molecular glues are not restricted to the agonistic/antagonistic features of a protein, thus massively expanding the range of the druggable proteome. Also, the molecular glue itself is not degraded in the process and can trigger the degradation process several times over, thus leading to longer-lasting therapeutic effects.
About Evotec's strategic collaboration with Bristol Myers Squibb in molecular glues
In 2018, Evotec entered a long-term strategic drug discovery and development collaboration in the field of molecular glues with Celgene, now Bristol Myers Squibb. Bristol Myers Squibb is a leader in this field based on its unique library of CELMoDs™. The collaboration aims to discover and develop a leading pipeline of molecular glue degraders for a range of therapeutic indications leveraging all of Evotec's proprietary PanOmics and PanHunter platforms as well as AI/ML-based drug discovery and development capabilities.
Evotec applies high-end proteomics and transcriptomics at industrial scale to profile and select promising drug candidates based on comprehensive cell biological profiles. Evotec's leading PanOmics screening capabilities are delivering unmatched throughput. The selection of the most promising candidates for drug development is facilitated by Evotec's PanOmics data analysis platform PanHunter. PanHunter supports the integration and analysis of these data sets and thereby enables the selection of the most promising CELMoDs™ for further progression into lead optimization.
About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision.
Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.
With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.
Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability.
With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.
Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec .
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For further information, please contact:
Media
Susanne Kreuter
VP Head of Strategic Marketing
Susanne.Kreuter@evotec.com
Investor Relations
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com
SOURCE: Evotec SE
View the original press release on ACCESS Newswire
FAQ
What did Evotec (EVO) announce on November 12, 2025 regarding Bristol Myers Squibb?
Why did Evotec (EVO) receive a US$5 million payment from Bristol Myers Squibb?
When is the CELMoD™ candidate from Evotec (EVO) expected to enter clinical trials?
How long has Evotec (EVO) been collaborating with Bristol Myers Squibb on protein degradation?
Does the IND acceptance for the Evotec (EVO) candidate mean it is proven effective?
Will the US$5 million milestone materially change Evotec (EVO) financials?
